Although responses to PD‐L1/PD‐1‐targeting therapy have been documented even in cancers where PD‐L1 expression was low, high PD‐L1 expression is often used as a biomarker and predictor of response to PD‐L1/PD‐1‐targeting therapy in several types of cancer, including Hodgkin lymphoma.21, 23, 38, 39, 40. Here, CD274 is linked to cancer.